Jonathan Tobin
Non Executive Director at Adendra Therapeutics
London, England
Overview
Work Experience
Partner
2021 - Current
I'm focused on leading investments in biotech companies globally. jtobin@bcpvc.com
Investor-in-Residence
2023
As investor-in-residence I am advising the CRH Seed fund team on their early stage investments in start-ups based on the ground breaking research emerging from Cancer Research UK laboratories.
Non Executive Director
2023
Non Executive Director
2021
Non Executive Director
2022
First-in-class anti-GDF15 mAb in Phase 2 in solid tumour patients
Non Executive Director
2022
Non Executive Director
2022
Member of the Investment Advisory Committee
2020
KHAN-I is a new fund backed by the Max Planck Foundation, European Investment Fund, and Austrian government to back early stage drug discovery projects originating from Germany and Austria to create new biotech opportunities.
Commercial Partnerships Advisor
2021 - 2021
Large consultancy project advising Genomics England on part of their commercial strategy
Managing Director
2016 - 2021
Investments in public and private life science companies, specialising in biotech investments. Involved in investments in Artios Pharma, VelosBio (acquired by Merck), Depixus, STipe Therapeutics, Atox Bio, Quench Bio, Pyxis Oncology (NASDAQ), TwelveBio (acquired by Ensoma), Gensight (Euronext).